Long-Term Success in the Management of an Extensive Medial Canthal Basal-Cell Carcinoma with Vismodegib
Purpose: To present a case of an extensive basal-cell carcinoma (BCC) of the medial canthus that was successfully treated with vismodegib. The introduction of vismodegib and other Hedgehog pathway inhibitors into clinical practice has provided a new option for the nonsurgical management of periocula...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-07-01
|
| Series: | Journal of Current Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/joco.joco_76_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Purpose:
To present a case of an extensive basal-cell carcinoma (BCC) of the medial canthus that was successfully treated with vismodegib. The introduction of vismodegib and other Hedgehog pathway inhibitors into clinical practice has provided a new option for the nonsurgical management of periocular BCC.
Methods:
An 85-year-old male was referred to our clinic with a pigmented nodular BCC but declined any medical intervention. Two years later, the patient returned with an extensive periocular lesion. Through biopsy and magnetic resonance imaging, we confirmed the diagnosis of a nodular-ulcerative BCC extending into the medial orbit. Surgery and radiotherapy were declined. Therefore, oral treatment with vismodegib was initiated.
Results:
After 3 months, complete tumor regression was noted, and the medication was discontinued. The patient remained tumor-free till the last follow-up, 3 years posttreatment. No treatment-related side effects were observed.
Conclusion:
This case demonstrates the clinical value of vismodegib in advanced periocular BCC, particularly when surgery is inappropriate or declined by the patient. |
|---|---|
| ISSN: | 2452-2325 |